Avalo Therapeutics (AVTX) director receives grant of 1,105 stock options

Rhea-AI Filing Summary

Avalo Therapeutics director Kevin Robert Lind received a new stock option grant. On June 30, 2026, he was awarded options covering 1,105 shares of Avalo common stock at an exercise price of $18.48 per share. The options are 100% vested at grant and expire on June 30, 2036, leaving him with 1,105 options outstanding after this transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lind Kevin Robert

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,105	$15.04	$17K

Holdings After Transaction: Stock Option (Right to Buy) — 1,105 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 1,105 options Exercise price: $18.48 per share Grant valuation metric: $15.04 per option +3 more

6 metrics

Options granted 1,105 options Stock option grant on June 30, 2026

Exercise price $18.48 per share Exercise price of granted stock options

Grant valuation metric $15.04 per option Transaction price per share for option grant

Expiration date June 30, 2036 Option term end date

Underlying shares 1,105 shares Avalo common stock underlying the options

Holdings after transaction 1,105 options Total derivative securities following grant

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, 100% vested

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

100% vested financial

"The options were granted on June 30, 2026, and are 100% vested."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:06 PM Accepted by SEC EDGAR 07/02/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lind Kevin Robert

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18.48	06/30/2026		A		1,105		(1)	06/30/2036	Common Stock	1,105	$15.04	1,105	D

Explanation of Responses:

1. The options were granted on June 30, 2026, and are 100% vested.

	/s/ Christopher Sullivan, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Avalo Therapeutics (AVTX) director Kevin Robert Lind report on this Form 4?

He reported receiving a grant of stock options covering 1,105 shares of Avalo Therapeutics common stock. The filing classifies this as a grant, award, or other acquisition rather than an open-market purchase or sale.

What are the key terms of Kevin Robert Lind’s new Avalo Therapeutics (AVTX) stock options?

The options cover 1,105 shares of common stock with an exercise price of $18.48 per share. They were granted on June 30, 2026, are fully vested at grant, and expire on June 30, 2036.

Is Kevin Robert Lind’s Avalo Therapeutics (AVTX) transaction a buy or a sale of shares?

It is neither a market buy nor a sale. The Form 4 shows a compensation-related grant of stock options, classified as a "Grant, award, or other acquisition" of derivative securities rather than an open-market transaction.

How many Avalo Therapeutics (AVTX) options does Kevin Robert Lind hold after this filing?

After this grant, he holds 1,105 stock options according to the Form 4. These options are fully vested at grant and relate to Avalo Therapeutics common stock as the underlying security.

When do Kevin Robert Lind’s Avalo Therapeutics (AVTX) stock options expire?

The options expire on June 30, 2036. Until that date, subject to plan terms, he may choose to exercise them at the fixed exercise price of $18.48 per share for Avalo common stock.